Dosing Strategy of Intravitreal Ranibizumab for Pathological Myopia Choroidal Neovascularization

• Status: Completed
• Trial end date: 2018-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the efficacy (times of injection, change of visual acuity and Cva/ I) and safety (macular visual function and choroidal thickness) of different dosing of ranibizumab intravitreal injection (1+PRN vs. 3+PRN) in treating with pathological myopia choroidal neovascularization (PM-CNV).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zhongshan Ophthalmic Center, Sun Yat-sen University
• Treatments: Ranibizumab

Criteria

Inclusion Criteria:

• older then 18 years old

• refractive error ≥ -6.0 diopters or axial length ≥ 26.0mm

• active CNV due to high myopic which is the only reason cause visual loss confirmed by fluorescein fundus angiography

• BCVA ≥ 24.0 and ≤73 letters at a starting distance of 4 meters using Early Treatment Diabetic Retinopathy Study visual acuity chart.

Exclusion Criteria:

• history of (a) stroke,(b) laser photocoagulation involved macular area in study eye, (c) intraocular treatment with corticosteroids or intraocular surgery or anti vascular endothelial growth factor or verteporfin photodynamic therapy within 6 months in study eye, or (d) hypersensitivity to ranibizumab or fluorescein

• presence of active infectious disease or confirmed intraocular pressure ≥ 21.0 mmHg

• pregnant or nursing women

• uncontrolled high blood pressure ≥ 150/90 mmHg or uncontrolled fasting blood glucose ≥ 7 mmol/L